Log In
Print
BCIQ
Print
Print this Print this
 

XMT-1107

  Manage Alerts
Collapse Summary General Information
Company Mersana Therapeutics Inc.
DescriptionFleximer-conjugated fumagillin analog
Molecular Target Methionine aminopeptidase 2 (MetAP2)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation

Partner

Teva Pharmaceutical Industries Ltd.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$334.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today